Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size
A
A
A

FDA: Prostate Cancer Drugs Raise Diabetes, Heart Risk

New Warnings for Eligard, Lupron, Trelstar, Viadur, Zoladex
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Mature man deep in thought

Oct. 20, 2010 -- A class of drugs used to treat advanced prostate cancer raises patients' risk of diabetes, heart disease, and stroke, the FDA today warned.

The five drugs, gonadotropin-releasing hormone (GnRH) agonists, are approved for the treatment of advanced prostate cancer. They are:

  • Eligard
  • Lupron
  • Trelstar
  • Viadur
  • Zoladex

All of the drugs will stay on the market but will be required to carry new label warnings.

The risk that the drugs will trigger diabetes or heart disease/stroke appear small, the FDA says. But recent studies suggest that doctors should monitor blood sugar levels and watch for signs of heart disease in men taking these drugs.

Patients should not stop taking these drugs, but should discuss any concerns with their doctors.

Before beginning treatment with any of these drugs, patients should tell their doctors whether they've ever had diabetes, heart disease, a heart attack, or a stroke. They should also report any history of high blood pressure, high cholesterol, or cigarette smoking.

Today's FDA action follows the agency's announcement last May that it was reviewing safety concerns raised by new data on GnRH agonists.

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article